Environmental issues in thyroid diseases

Frontiers in Endocrinology

Volumn 8, Issue MAR, 2017, Pages

  Ferrari, Silvia Martina ^a   Fallahi, Poupak ^a   Antonelli, Alessandro ^a   Benvenga, Salvatore ^b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Antithyroid antibodies; Autoimmune thyroid diseases; Environmental influences; Genetic influences; Thyroid cancer

Indexed keywords

AMIODARONE; BROMINE DERIVATIVE; HEAVY METAL; IODINE; POLYCHLORINATED BIPHENYL DERIVATIVE; PREALBUMIN; SELENIUM; THYROXINE; VITAMIN D;

AUTOIMMUNITY; DIETARY INTAKE; DISEASE ASSOCIATION; ENDOCRINE OPHTHALMOPATHY; ENVIRONMENTAL IMPACT; GENETIC SUSCEPTIBILITY; HEPATITIS C VIRUS; HUMAN; HUMAN PARVOVIRUS B19; HYPERTHYROIDISM; HYPOTHYROIDISM; IMMUNOREACTIVITY; META ANALYSIS (TOPIC); NONHUMAN; RADIATION EXPOSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SHORT SURVEY; SMOKING; THYROID CANCER; THYROID DISEASE; THYROID FUNCTION; VIRUS INFECTION;

EID: 85017164122     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2017.00050     Document Type: Short Survey

References (120)

1. Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol (1997) 84:223-43. doi: 10.1006/clin.1997.4412
2. Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) (1995) 43:55-68. doi:10.1111/j.1365-2265.1995.tb01894.x
3. Pearce SH, Leech NJ. Toward precise forecasting of autoimmune endocrinopathy. J Clin Endocrinol Metab (2004) 89:544-7. doi:10.1210/jc.2003-032142
4. Ngo ST, Steyn FJ, McCombe PA. Gender differences in autoimmune disease. Front Neuroendocrinol (2014) 35:347-69. doi:10.1016/j.yfrne.2014.04.004
5. McCombe PA, Greer JM. Female reproductive issues in multiple sclerosis. Mult Scler (2013) 19:392-402. doi:10.1177/1352458512452331
6. McKean KA, Nunney L. Bateman's principle and immunity: phenotypically plastic reproductive strategies predict changes in immunological sex differences. Evolution (2005) 59:1510-7. doi:10.1554/04-657
7. Hewagama A, Richardson B. The genetics and epigenetics of autoimmune diseases. J Autoimmun (2009) 33:3-11. doi:10.1016/j.jaut.2009.03.007
8. Brix TH, Hegedüs L. Twin studies as a model for exploring the aetiology of autoimmune thyroid disease. Clin Endocrinol (2012) 76:457-64. doi:10.1111/j.1365-2265.2011.04318.x
9. Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf) (1977) 7:481-9. doi:10.1111/j.1365-2265.1977.tb01340.x
10. McLeod DS, Cooper DS. The incidence and prevalence of thyroid autoimmunity. Endocrine (2012) 42:252-65. doi:10.1007/s12020-012-9703-2
11. Pedersen IB, Laurberg P, Knudsen N, Jørgensen T, Perrild H, Ovesen L, et al. An increased incidence of overt hypothyroidism after iodine fortification of salt in Denmark: a prospective population study. J Clin Endocrinol Metab (2007) 92:3122-7. doi:10.1210/jc.2007-0732
12. Rizzo M, Rossi RT, Bonaffini O, Scisca C, Altavilla G, Calbo L, et al. Increased annual frequency of Hashimoto's thyroiditis between years 1988 and 2007 at a cytological unit of Sicily. Ann Endocrinol (Paris) (2010) 71:525-34. doi:10.1016/j.ando.2010.06.006
13. Tomer Y, Davies TF. Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function. Endocr Rev (2003) 24:694-717. doi:10.1210/er.2002-0030
14. Hansen PS, Brix TH, Iachine I, Kyvik KO, Hegedüs L. The relative importance of genetic and environmental effects for the early stages of thyroid autoimmunity: a study of healthy Danish twins. Eur J Endocrinol (2006) 154:29-38. doi:10.1530/eje.1.02060
15. Simmonds MJ. GWAS in autoimmune thyroid disease: redefining our understanding of pathogenesis. Nat Rev Endocrinol (2013) 9:277-87. doi:10.1038/nrendo.2013.56
16. Tomer Y, Ban Y, Concepcion E, Barbesino G, Villanueva R, Greenberg DA, et al. Common and unique susceptibility loci in Graves and Hashimoto diseases: results of whole-genome screening in a data set of 102 multiplex families. Am J Hum Genet (2003) 73:736-47. doi:10.1086/378588
17. Kawashima A, Tanigawa K, Akama T, Yoshihara A, Ishii N, Suzuki K. Innate immune activation and thyroid autoimmunity. J Clin Endocrinol Metab (2011) 96:3661-71. doi:10.1210/jc.2011-1568
18. Benvenga S, Antonelli A, Vita R. Thyroid nodules and thyroid autoimmunity in the context of environmental pollution. Rev Endocr Metab Disord (2015) 16:319-40. doi:10.1007/s11154-016-9327-6
19. Agate L, Mariotti S, Elisei R, Mossa P, Pacini F, Molinaro E, et al. Thyroid autoantibodies and thyroid function in subjects exposed to Chernobyl fallout during childhood: evidence for a transient radiation-induced elevation of serum thyroid antibodies without an increase in thyroid autoimmune disease. J Clin Endocrinol Metab (2008) 93:2729-36. doi:10.1210/jc.2008-0060
20. Tronko MD, Brenner AV, Olijnyk VA, Robbins J, Epstein OV, McConnell RJ, et al. Autoimmune thyroiditis and exposure to iodine 131 in the Ukrainian cohort study of thyroid cancer and other thyroid diseases after the Chernobyl accident: results from the first screening cycle (1998-2000). J Clin Endocrinol Metab (2006) 91:4344-51. doi:10.1210/jc.2006-0498
21. Dunkelmann S, Wolf R, Koch A, Kittner C, Groth P, Schuemichen C. Incidence of radiation-induced Graves' disease in patients treated with radioiodine for thyroid autonomy before and after introduction of a high-sensitivity TSH receptor antibody assay. Eur J Nucl Med Mol Imaging (2004) 31:1428-34. doi:10.1007/s00259-004-1519-8
22. Blitzer JB, Paolozzi FP, Gottlieb AJ, Zamkoff KW, Chung CT. Thyrotoxic thyroiditis after radiotherapy for Hodgkin's disease. Arch Intern Med (1985) 145:1734-5. doi:10.1001/archinte.1985.00360090210034
23. Bryer-Ash M, Lodhi W, Robbins K, Morrison R. Early thyrotoxic thyroiditis after radiotherapy for tonsillar carcinoma. Arch Otolaryngol Head Neck Surg (2001) 127:209-11. doi:10.1001/archotol.127.2.209
24. Papanastasiou L, Vatalas IA, Koutras DA, Mastorakos G. Thyroid autoimmunity in the current iodine environment. Thyroid (2007) 17:729-39. doi:10.1089/thy.2006.0299
25. Laurberg P, Jørgensen T, Perrild H, Ovesen L, Knudsen N, Pedersen IB, et al. The Danish investigation on iodine intake and thyroid disease, DanThyr: status and perspectives. Eur J Endocrinol (2006) 155:219-28. doi:10.1530/eje.1.02210
26. Luo Y, Kawashima A, Ishido Y, Yoshihara A, Oda K, Hiroi N, et al. Iodine excess as an environmental risk factor for autoimmune thyroid disease. Int J Mol Sci (2014) 15:12895-912. doi:10.3390/ijms150712895
27. Wiersinga WM. Clinical relevance of environmental factors in the pathogenesis of autoimmune thyroid disease. Endocrinol Metab (Seoul) (2016) 31:213-22. doi:10.3803/EnM.2016.31.2.213
28. Lacka K, Szeliga A. Significance of selenium in thyroid physiology and pathology. Pol Merkur Lekarski (2015) 38:348-53
29. Duntas LH. Selenium and the thyroid: a close-knit connection. J Clin Endocrinol Metab (2010) 95:5180-8. doi:10.1210/jc.2010-0191
30. Wu Q, Rayman MP, Lv H, Schomburg L, Cui B, Gao C, et al. Low population selenium status is associated with increased prevalence of thyroid disease. J Clin Endocrinol Metab (2015) 100:4037-47. doi:10.1210/jc.2015-2222
31. Esposito D, Rotondi M, Accardo G, Vallone G, Conzo G, Docimo G, et al. Influence of short-term selenium supplementation on the natural course of Hashimoto's thyroiditis: clinical results of a blinded placebo-controlled randomized prospective trial. J Endocrinol Invest (2017) 40:83-9. doi:10.1007/s40618-016-0535-4
32. Bartalena L, Martino E, Marcocci C, Bogazzi F, Panicucci M, Velluzzi F, et al. More on smoking habits and Graves' ophthalmopathy. J Endocrinol Invest (1989) 12:733-7. doi:10.1007/BF03350047
33. Ericsson UB, Lindgärde F. Effects of cigarette smoking on thyroid function and the prevalence of goitre, thyrotoxicosis and autoimmune thyroiditis. J Intern Med (1991) 229:67-71. doi:10.1111/j.1365-2796.1991.tb00308.x
34. Vestergaard P. Smoking and thyroid disorders-a meta-analysis. Eur J Endocrinol (2002) 146:153-61. doi:10.1530/eje.0.1460153
35. Strieder TG, Prummel MF, Tijssen JG, Endert E, Wiersinga WM. Risk factors for and prevalence of thyroid disorders in a cross-sectional study among healthy female relatives of patients with autoimmune thyroid disease. Clin Endocrinol (Oxf) (2003) 59:396-401. doi:10.1046/j.1365-2265.2003.01862.x
36. Belin RM, Astor BC, Powe NR, Ladenson PW. Smoke exposure is associated with a lower prevalence of serum thyroid autoantibodies and thyrotropin concentration elevation and a higher prevalence of mild thyrotropin concentration suppression in the third National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab (2004) 89:6077-86. doi:10.1210/jc.2004-0431
37. Pedersen IB, Laurberg P, Knudsen N, Jørgensen T, Perrild H, Ovesen L, et al. Smoking is negatively associated with the presence of thyroglobulin autoantibody and to a lesser degree with thyroid peroxidase autoantibody in serum: a population study. Eur J Endocrinol (2008) 158:367-73. doi:10.1530/EJE-07-0595
38. Effraimidis G, Tijssen JG, Wiersinga WM. Discontinuation of smoking increases the risk for developing thyroid peroxidase antibodies and/or thyroglobulin antibodies: a prospective study. J Clin Endocrinol Metab (2009) 94:1324-8. doi:10.1210/jc.2008-1548
39. Effraimidis G, Strieder TG, Tijssen JG, Wiersinga WM. Natural history of the transition from euthyroidism to overt autoimmune hypo-or hyperthyroidism: a prospective study. Eur J Endocrinol (2011) 164:107-13. doi:10.1530/EJE-10-0785
40. Rendina D, De Palma D, De Filippo G, De Pascale F, Muscariello R, Ippolito R, et al. Prevalence of simple nodular goiter and Hashimoto's thyroiditis in current, previous, and never smokers in a geographical area with mild iodine deficiency. Horm Metab Res (2015) 47:214-9. doi:10.1055/s-0034-1387702
41. Galanti MR, Cnattingius S, Granath F, Ekbom-Schnell A, Ekbom A. Smoking and environmental iodine as risk factors for thyroiditis among parous women. Eur J Epidemiol (2007) 22:467-72. doi:10.1007/s10654-007-9142-1
42. Wiersinga WM. Smoking and thyroid. Clin Endocrinol (Oxf) (2013) 79:145-51. doi:10.1111/cen.12222
43. Nizri E, Irony-Tur-Sinai M, Lory O, Orr-Urtreger A, Lavi E, Brenner T. Activation of the cholinergic anti-inflammatory system by nicotine attenuates neuroinflammation via suppression of Th1 and Th17 responses. J Immunol (2009) 183:6681-8. doi:10.4049/jimmunol.0902212
44. Balazs C, Stenszky V, Farid NR. Association between Graves' ophthalmopathy and smoking. Lancet (1990) 336:754. doi:10.1016/0140-6736(90)92251-C
45. Tellez M, Cooper J, Edmonds C. Graves' ophthalmopathy in relation to cigarette smoking and ethnic origin. Clin Endocrinol (Oxf) (1992) 36:291-4. doi:10.1111/j.1365-2265.1992.tb01445.x
46. Vestergaard P, Rejnmark L, Weeke J, Hoeck HC, Nielsen HK, Rungby J, et al. Smoking as a risk factor for Graves' disease, toxic nodular goiter, and autoimmune hypothyroidism. Thyroid (2002) 12:69-75. doi:10.1089/105072502753451995
47. Holm IA, Manson JE, Michels KB, Alexander EK, Willett WC, Utiger RD. Smoking and other lifestyle factors and the risk of Graves' hyperthyroidism. Arch Intern Med (2005) 165:1606-11. doi:10.1001/archinte.165.14.1606
48. Glinoer D, de Nayer P, Bex M; Belgian Collaborative Study Group on Graves' Disease. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. Eur J Endocrinol (2001) 144:475-83. doi:10.1530/eje.0.1440475
49. Regensburg NI, Wiersinga WM, Berendschot TT, Saeed P, Mourits MP. Effect of smoking on orbital fat and muscle volume in Graves' orbitopathy. Thyroid (2011) 21:177-81. doi:10.1089/thy.2010.0218
50. Bartalena L, Marcocci C, Tanda ML, Manetti L, Dell'Unto E, Bartolomei MP, et al. Cigarette smoking and treatment outcomes in Graves ophthalmopathy. Ann Intern Med (1998) 129:632-5. doi:10.7326/0003-4819-129-8-199810150-00010
51. Träisk F, Tallstedt L, Abraham-Nordling M, Andersson T, Berg G, Calissendorff J, et al. Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab (2009) 94:3700-7. doi:10.1210/jc.2009-0747
52. Hou X, Li Y, Li J, Wang W, Fan C, Wang H, et al. Development of thyroid dysfunction and autoantibodies in Graves' multiplex families: an eight-year follow-up study in Chinese Han pedigrees. Thyroid (2011) 21:1353-8. doi:10.1089/thy.2011.0035
53. Anagnostis P, Adamidou F, Polyzos SA, Katergari S, Karathanasi E, Zouli C, et al. Predictors of long-term remission in patients with Graves' disease: a single center experience. Endocrine (2013) 44:448-53. doi:10.1007/s12020-013-9895-0
54. Metcalfe RA, Weetman AP. Stimulation of extraocular muscle fibroblasts by cytokines and hypoxia: possible role in thyroid-associated ophthalmopathy. Clin Endocrinol (Oxf) (1994) 40:67-72. doi:10.1111/j.1365-2265.1994.tb02445.x
55. Burch HB, Lahiri S, Bahn RS, Barnes S. Superoxide radical production stimulates retroocular fibroblast proliferation in Graves' ophthalmopathy. Exp Eye Res (1997) 65:311-6. doi:10.1006/exer.1997.0353
56. Bartalena L, Tanda ML, Piantanida E, Lai A. Oxidative stress and Graves' ophthalmopathy: in vitro studies and therapeutic implications. Biofactors (2003) 19:155-63. doi:10.1002/biof.5520190308
57. Bufalo NE, Santos RB, Cury AN, Andrade RA, Morari J, Morari EC, et al. Genetic polymorphisms associated with cigarette smoking and the risk of Graves' disease. Clin Endocrinol (Oxf) (2008) 68:982-7. doi:10.1111/j.1365-2265.2007.03121.x
58. Planck T, Shahida B, Parikh H, Ström K, Asman P, Brorson H, et al. Smoking induces overexpression of immediate early genes in active Graves' ophthalmopathy. Thyroid (2014) 24:1524-32. doi:10.1089/thy.2014.0153
59. Desailloud R, Hober D. Viruses and thyroiditis: an update. Virol J (2009) 6:5. doi:10.1186/1743-422X-6-5
60. Parsa AA, Bhangoo A. HIV and thyroid dysfunction. Rev Endocr Metab Disord (2013) 14:127-31. doi:10.1007/s11154-013-9248-6
61. Morohoshi K, Takahashi Y, Mori K. Viral infection and innate pattern recognition receptors in induction of Hashimoto's thyroiditis. Discov Med (2011) 12:505-11
62. Servant-Delmas A, Morinet F. Update of the human parvovirus B19 biology. Transfus Clin Biol (2016) 23:5-12. doi:10.1016/j.tracli.2015.11.006
63. Lehmann HW, Lutterbüse N, Plentz A, Akkurt I, Albers N, Hauffa BP, et al. Association of parvovirus B19 infection and Hashimoto's thyroiditis in children. Viral Immunol (2008) 21:379-83. doi:10.1089/vim.2008.0001
64. Wang JH, Zhang WP, Liu HX, Wang D, Li YF, Wang WQ, et al. Detection of human parvovirus B19 in papillary thyroid carcinoma. Br J Cancer (2008) 98:611-8. doi:10.1038/sj.bjc.6604196
65. Adamson LA, Fowler LJ, Clare-Salzler MJ, Hobbs JA. Parvovirus B19 infection in Hashimoto's thyroiditis, papillary thyroid carcinoma, and anaplastic thyroid carcinoma. Thyroid (2011) 21:411-7. doi:10.1089/thy.2010.0307
66. Page C, Hoffmann TW, Benzerdjeb N, Duverlie G, Sevestre H, Desailloud R. Detection of erythrovirus B19 in thyroidectomy specimens from Graves' disease patients: a case-control study. J Med Virol (2013) 85:1414-9. doi:10.1002/jmv.23595
67. Page C, Hoffmann TW, Benzerdjeb N, Desailloud R, Sevestre H, Duverlie G. Immunohistochemical-and PCR-based assay for the reproducible, routine detection of erythrovirus B19 in thyroid tissues. J Med Virol (2015) 87:1054-9. doi:10.1002/jmv.24147
68. Wang L, Zhang WP, Yao L, Zhang W, Zhu J, Zhang WC, et al. PRDM1 expression via human parvovirus B19 infection plays a role in the pathogenesis of Hashimoto thyroiditis. Hum Pathol (2015) 46:1913-21. doi:10.1016/j.humpath.2015.08.009
69. Page C, Duverlie G, Sevestre H, Desailloud R. Erythrovirus B19 and autoimmune thyroid diseases. Review of the literature and pathophysiological hypotheses. J Med Virol (2015) 87:162-9. doi:10.1002/jmv.23963
70. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol (2007) 13:2436-41. doi:10.3748/wjg.v13.i17.2436
71. Blackard JT, Kemmer N, Sherman KE. Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences. Hepatology (2006) 44:15-22. doi:10.1002/hep.21283
72. Stefanova-Petrova DV, Tzvetanska AH, Naumova EJ, Mihailova AP, Hadjiev EA, Dikova RP, et al. Chronic hepatitis C virus infection: prevalence of extrahepatic manifestations and association with cryoglobulinemia in Bulgarian patients. World J Gastroenterol (2007) 13:6518-28. doi:10.3748/wjg.13.6518
73. Galossi A, Guarisco R, Bellis L, Puoti C. Extrahepatic manifestations of chronic HCV infection. J Gastrointestin Liver Dis (2007) 16:65-73
74. Pastore F, Martocchia A, Stefanelli M, Prunas P, Giordano S, Toussan L, et al. Hepatitis C virus infection and thyroid autoimmune disorders: a model of interactions between the host and the environment. World J Hepatol (2016) 8:83-91. doi:10.4254/wjh.v8.i2.83
75. Fernandez-Soto L, Gonzalez A, Escobar-Jimenez F, Vazquez R, Ocete E, Olea N, et al. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Arch Intern Med (1998) 158:1445-8. doi:10.1001/archinte.158.13.1445
76. Preziati D, La Rosa L, Covini G, Marcelli R, Rescalli S, Persani L, et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol (1995) 132:587-93. doi:10.1530/eje.0.1320587
77. Antonelli A, Ferri C, Pampana A, Fallahi P, Nesti C, Pasquini M, et al. Thyroid disorders in chronic hepatitis C. Am J Med (2004) 117:10-3. doi:10.1016/j.amjmed.2004.01.023
78. Tran A, Quaranta JF, Benzaken S, Thiers V, Chau HT, Hastier P, et al. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology (1993) 18:253-7. doi:10.1002/hep.1840180205
79. Metcalfe RA, Ball G, Kudesia G, Weetman AP. Failure to find an association between hepatitis C virus and thyroid autoimmunity. Thyroid (1997) 7:421-4. doi:10.1089/thy.1997.7.421
80. Boadas J, Rodríguez-Espinosa J, Enríquez J, Miralles F, Martínez-Cerezo FJ, González P, et al. Prevalence of thyroid autoantibodies is not increased in blood donors with hepatitis C virus infection. J Hepatol (1995) 22:611-5. doi:10.1016/0168-8278(95)80216-9
81. Indolfi G, Stagi S, Bartolini E, Salti R, de Martino M, Azzari C, et al. Thyroid function and anti-thyroid autoantibodies in untreated children with vertically acquired chronic hepatitis C virus infection. Clin Endocrinol (Oxf) (2008) 68:117-21. doi:10.1111/j.1365-2265.2007.03009.x
82. Giordano TP, Henderson L, Landgren O, Chiao EY, Kramer JR, El-Serag H, et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA (2007) 297:2010-7. doi:10.1001/jama.297.18.2010
83. Watanabe U, Hashimoto E, Hisamitsu T, Obata H, Hayashi N. The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. Am J Gastroenterol (1994) 89:399-403
84. Carella C, Amato G, Biondi B, Rotondi M, Morisco F, Tuccillo C, et al. Longitudinal study of antibodies against thyroid in patients undergoing interferon-alpha therapy for HCV chronic hepatitis. Horm Res (1995) 44:110-4. doi:10.1159/000184606
85. Roti E, Minelli R, Giuberti T, Marchelli S, Schianchi C, Gardini E, et al. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am J Med (1996) 101:482-7. doi:10.1016/S0002-9343(96)00259-8
86. Marazuela M, García-Buey L, González-Fernández B, García-Monzón C, Arranz A, Borque MJ, et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol (Oxf) (1996) 44:635-42. doi:10.1046/j.1365-2265.1996.751768.x
87. Carella C, Mazziotti G, Morisco F, Rotondi M, Cioffi M, Tuccillo C, et al. The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism. Eur J Endocrinol (2002) 146:743-9. doi:10.1530/eje.0.1460743
88. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Ghinoi A, Rotondi M, et al. Thyroid disorders in chronic hepatitis C virus infection. Thyroid (2006) 16:563-72. doi:10.1089/thy.2006.16.563
89. Antonelli A, Ferri C, Fallahi P, Giuggioli D, Nesti C, Longombardo G, et al. Thyroid involvement in patients with overt HCV-related mixed cryoglobulinaemia. QJM (2004) 97:499-506. doi:10.1093/qjmed/hch088
90. Antonelli A, Ferri C, Galeazzi M, Giannitti C, Manno D, Mieli-Vergani G, et al. HCV infection: pathogenesis, clinical manifestations and therapy. Clin Exp Rheumatol (2008) 26:S39-47
91. Antonelli A, Ferri C, Fallahi P. Thyroid cancer in patients with hepatitis C infection. JAMA (1999) 281:1588. doi:10.1001/jama.281.17.1588
92. Montella M, Crispo A, Pezzullo L, Izzo F, Fabbrocini G, Ronga D, et al. Is hepatitis C virus infection associated with thyroid cancer? A case-control study. Int J Cancer (2000) 87:611-2. doi:10.1002/1097-0215(20000815)87:4<611::AID-IJC24>3.0.CO;2-N
93. Montella M, Crispo A, de Bellis G, Izzo F, Frigeri F, Ronga D, et al. HCV and cancer: a case-control study in a high-endemic area. Liver (2001) 21:335-41. doi:10.1034/j.1600-0676.2001.210506.x
94. Fiore E, Rago T, Latrofa F, Provenzale MA, Piaggi P, Delitala A, et al. Hashimoto's thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with l-thyroxine. Endocr Relat Cancer (2011) 18:429-37. doi:10.1530/ERC-11-002
95. Antonelli A, Ferri C, Fallahi P, Pampana A, Ferrari SM, Barani L, et al. Thyroid cancer in HCV-related chronic hepatitis patients: a case-control study. Thyroid (2007) 17:447-51. doi:10.1089/thy.2006.0194
96. Antonelli A, Ferri C, Fallahi P, Nesti C, Zignego AL, Maccheroni M. Thyroid cancer in HCV-related mixed cryoglobulinemia patients. Clin Exp Rheumatol (2002) 20:693-6
97. Ferri C, Antonelli A, Mascia MT, Sebastiani M, Fallahi P, Ferrari D, et al. HCV-related autoimmune and neoplastic disorders: the HCV syndrome. Dig Liver Dis (2007) 39:S13-21. doi:10.1016/S1590-8658(07)80005-3
98. Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis (2012) 206:469-77. doi:10.1093/infdis/jis385
99. Antonelli A, Fazzi P, Fallahi P, Ferrari SM, Ferrannini E. Prevalence of hypothyroidism and Graves disease in sarcoidosis. Chest (2006) 130:526-32. doi:10.1378/chest.130.2.526
100. Antonelli A, Fallahi P, Mosca M, Ferrari SM, Ruffilli I, Corti A, et al. Prevalence of thyroid dysfunctions in systemic lupus erythematosus. Metabolism (2010) 59:896-900. doi:10.1016/j.metabol.2009
101. Vagenakis AG, Braverman LE. Adverse effects of iodides on thyroid function. Med Clin North Am (1975) 59:1075-88. doi:10.1016/S0025-7125(16)31958-7
102. Danzi S, Klein I. Amiodarone-induced thyroid dysfunction. J Intensive Care Med (2015) 30:179-85. doi:10.1177/0885066613503278
103. Padmanabhan H. Amiodarone and thyroid dysfunction. South Med J (2010) 103:922-30. doi:10.1097/SMJ.0b013e3181e90500
104. Cohen-Lehman J, Dahl P, Danzi S, Klein I. Effects of amiodarone therapy on thyroid function. Nat Rev Endocrinol (2010) 6:34-41. doi:10.1038/nrendo.2009.225
105. Virili C, Centanni M. Does microbiota composition affect thyroid homeostasis? Endocrine (2015) 49:583-7. doi:10.1007/s12020-014-0509-2
106. Kmiec P, Sworczak K. Vitamin D in thyroid disorders. Exp Clin Endocrinol Diabetes (2015) 123:386-93. doi:10.1055/s-0035-1554714
107. Bizzaro G, Shoenfeld Y. Vitamin D and autoimmune thyroid diseases: facts and unresolved questions. Immunol Res (2015) 61:46-52. doi:10.1007/s12026-014-8579-z
108. Wang J, Lv S, Chen G, Gao C, He J, Zhong H, et al. Meta-analysis of the association between vitamin D and autoimmune thyroid disease. Nutrients (2015) 7:2485-98. doi:10.3390/nu7042485
109. D'Aurizio F, Villalta D, Metus P, Doretto P, Tozzoli R. Is vitamin D a player or not in the pathophysiology of autoimmune thyroid diseases? Autoimmun Rev (2015) 14:363-9. doi:10.1016/j.autrev.2014.10.008
110. Boas M, Feldt-Rasmussen U, Main KM. Thyroid effects of endocrine disrupting chemicals. Mol Cell Endocrinol (2012) 355:240-8. doi:10.1016/j.mce.2011.09.005
111. Pearce EN, Braverman LE. Environmental pollutants and the thyroid. Best Pract Res Clin Endocrinol Metab (2009) 23:801-13. doi:10.1016/j.beem.2009.06.003
112. Hagmar L. Polychlorinated biphenyls and thyroid status in humans: a review. Thyroid (2003) 13:1021-8. doi:10.1089/105072503770867192
113. El Majidi N, Bouchard M, Carrier G. Systematic analysis of the relationship between standardized biological levels of polychlorinated biphenyls and thyroid function in pregnant women and newborns. Chemosphere (2014) 98:1-17. doi:10.1016/j.chemosphere.2013.10.006
114. Rochester JR. Bisphenol A and human health: a review of the literature. Reprod Toxicol (2013) 42:132-55. doi:10.1016/j.reprotox.2013.08.008
115. Jancic SA, Stosic BZ. Cadmium effects on the thyroid gland. Vitam Horm (2014) 94:391-425. doi:10.1016/B978-0-12-800095-3.00014-6
116. Soldin OP, Aschner M. Effects of manganese on thyroid hormone homeostasis: potential links. Neurotoxicology (2007) 28:951-6. doi:10.1016/j.neuro.2007.05.003
117. Vigneri R, Malandrino P, Gianì F, Russo M, Vigneri P. Heavy metals in the volcanic environment and thyroid cancer. Mol Cell Endocrinol (2016) 30438-30435. doi:10.1016/j.mce.2016.10.027
118. Prummel MF, Wiersinga WM. Smoking and risk of Graves' disease. JAMA (1993) 269:479-82. doi:10.1001/jama.1993.03500040045034
119. Duntas LH, Stathatos N. Toxic chemicals and thyroid function: hard facts and lateral thinking. Rev Endocr Metab Disord (2015) 6:311-8. doi:10.1007/s11154-016-9331-x
120. Brent GA. Environmental exposures and autoimmune thyroid disease. Thyroid (2010) 20:755-61. doi:10.1089/thy.2010.1636